Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 2 (3)

Trial Status

Recruiting1
Unknown1
Withdrawn1

Clinical Trials (3)

Showing 3 of 3 trials
NCT06413992Phase 2Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

NCT04510584Phase 2Withdrawn

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

NCT04023916Phase 2Unknown

Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.

Showing all 3 trials

Research Network

Activity Timeline